Acute Kidney Injury and Ultra-endurance Running

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorArizona State University

About this trial

This study aims to understand how participating in the Western States Endurance Run (WSER), a 100-mile ultramarathon, affects kidney health. Long, strenuous exercise in hot conditions can temporarily strain the kidneys, especially when combined with dehydration, muscle breakdown, and the use of common pain-relief medications such as ibuprofen. Although kidney stress has been reported in endurance sports, no study has examined it directly in runners during the WSER using newer, more sensitive urine markers of kidney injury. Runners who volunteer will complete brief assessments before and after the race. These include providing a urine sample, a small finger-prick blood sample, a body-weight measurement, and answering a short questionnaire about pain-medication use. During the race, participants will wear a global positioning system (GPS) watch and heart-rate strap to monitor effort. Each assessment takes about 15 minutes, and no follow-up is required. Findings from this study will help determine how often kidney stress occurs in this event and what factors may contribute to it, ultimately supporting safer training and medical practices for ultramarathon athletes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Running in the Western States Endurance Run in either 2026, 2027 or 2028

No contraindications to exercise as indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) as prepared by the American College of Sports Medicine (ACSM)

Not currently taking medicine or experiencing illness that may influence the cardiovascular or neuromuscular system

Age ≥18 and ≤ 50 years old and injury free (skeletal muscle) for > 3 months

Disqualifiers

Minors (under 18)

Adults who are unable to consent (impaired decision-making capacity)

Prisoners

Pregnant Women

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sodium Bicarbonate (NaHCO3)

    Dietary supplement

    SB will be used to investigate whether adding a buffer exogenously to aid recovery helps in reducing the severity of acute kidney injury.

  • Placebo

    Dietary supplement

    The placebo product consists of the same sodium concentration as the intervention group receiving sodium bicarbonate.

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: sodium bicarbonateExperimental treatment 1 intervention
Group B: placeboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2), and neutrophil gelatinase-associated lipocalin (NGAL)

urine biomarkers of acute kidney injury

Time frame
one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Arizona State University

Lead sponsor

Western States Endurance Run Research Foundation

Collaborator

This trial is not recruiting at the moment. You can still explore other options: